12 Jun , 2025 By : Debdeep Gupta
Zydus Lifesciences share price gained more than a percent in the opening trade on June 12 following the company received the Establishment Inspection Report (EIR) report from the USFDA.
At 09:19am, Zydus Lifesciences was quoting at Rs 991.65, up Rs 12.90, or 1.32 percent, on the BSE.
".... has received the Establishment Inspection Report (EIR) report from the USFDA for the inspection conducted at its API manufacturing facility located at Ankleshwar," company said.
This facility underwent an inspection Between 10-14 March, 2025, and the inspection has been classified as No Action Indicated (NAI). The USFDA has concluded that this inspection is “closed”, it added.
Earlier in this month, the company announced a strategic entry into the global biologics contract development and manufacturing organization (CDMO) business by acquiring two U.S.-based biologics manufacturing facilities from Agenus Inc. and Agenus West LLC.
The deal involves an upfront payment of $75 million, with an additional contingent payment of up to $50 million over three years, dependent on the achievement of certain revenue milestones.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug firm said in a regulatory filing.
Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
The share touched a 52-week high of Rs 1,323.90 and a 52-week low of Rs 797.05 on 09 August, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 25.1 percent below its 52-week high and 24.42 percent above its 52-week low.
The market capitalisation of the company stands at Rs 99,783.19 crore.
0 Comment